SMOLEJ, L., C. ANDRÝS, Vladimír MAISNAR, Luděk POUR and J. MALÝ. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta medica (Hradec Králové). Hradec Králové, Czech Republic: Facultas Medica, Universitas Carolina, 2005, vol. 48, No 1, p. 57-58. ISSN 1211-4286.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.
Name in Czech Hladiny endoteliálního růstového faktoru a fibroblastového růstového faktoru v plazmě u lymfoproliferativních onemocnění
Authors SMOLEJ, L. (203 Czech Republic), C. ANDRÝS (203 Czech Republic), Vladimír MAISNAR (203 Czech Republic), Luděk POUR (203 Czech Republic, guarantor) and J. MALÝ (203 Czech Republic).
Edition Acta medica (Hradec Králové), Hradec Králové, Czech Republic, Facultas Medica, Universitas Carolina, 2005, 1211-4286.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/05:00035961
Organization unit Faculty of Medicine
Keywords (in Czech) angiogeneze; VEGF; bFGF;
Keywords in English Angiogenesis; VEGF; bFGF; Leukemia; Lymphoma; Myeloma
Tags angiogenesis, bFGF, leukemia, Lymphoma, myeloma, VEGF
Tags Reviewed
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 24/6/2009 11:33.
Abstract
Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn't find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin's lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients' survival.
Abstract (in Czech)
Publikace shnuje výsledky měření koncentrací plazmatických hladin VEGF a bFGF u pacientů s lymfoproliferativními onemocněními.
PrintDisplayed: 23/4/2021 14:18